Center for Systems and Computational Biology, The Wistar Institute, Philadelphia, Pennsylvania, USA.
J Proteome Res. 2011 Mar 4;10(3):1126-38. doi: 10.1021/pr1008866. Epub 2011 Jan 7.
Ectopic pregnancy (EP) and normal intrauterine pregnancy (IUP) serum proteomes were quantitatively compared to systematically identify candidate biomarkers. A 3-D biomarker discovery strategy consisting of abundant protein immunodepletion, SDS gels, LC-MS/MS, and label-free quantitation of MS signal intensities identified 70 candidate biomarkers with differences between groups greater than 2.5-fold. Further statistical analyses of peptide quantities were used to select the most promising 12 biomarkers for further study, which included known EP biomarkers, novel EP biomarkers (ADAM12 and ISM2), and five specific isoforms of the pregnancy specific beta-1-glycoprotein family. Technical replicates showed good reproducibility and protein intensities from the label-free discovery analysis compared favorably with reported abundance levels of several known reference serum proteins over at least 3 orders of magnitude. Similarly, relative abundances of candidate biomarkers from the label-free discovery analysis were consistent with relative abundances from pilot validation assays performed for five of the 12 most promising biomarkers using label-free multiple reaction monitoring of both the patient serum pools used for discovery and the individual samples that constituted these pools. These results demonstrate robust, reproducible, in-depth 3-D serum proteome discovery, and subsequent pilot-scale validation studies can be achieved readily using label-free quantitation strategies.
异位妊娠 (EP) 和正常宫内妊娠 (IUP) 的血清蛋白质组进行了定量比较,以系统地鉴定候选生物标志物。一种由丰富蛋白质免疫耗竭、SDS 凝胶、LC-MS/MS 和 MS 信号强度的无标记定量组成的 3-D 生物标志物发现策略,确定了 70 个候选生物标志物,这些标志物的组间差异大于 2.5 倍。对肽数量的进一步统计分析用于选择最有前途的 12 个生物标志物进行进一步研究,其中包括已知的 EP 生物标志物、新的 EP 生物标志物 (ADAM12 和 ISM2) 和妊娠特异性β-1-糖蛋白家族的五个特定同工型。技术重复显示出良好的重现性,并且无标记发现分析中的蛋白质强度与至少 3 个数量级范围内的几个已知参考血清蛋白的报道丰度水平相当。同样,从无标记发现分析中候选生物标志物的相对丰度与使用无标记多重反应监测对 12 个最有前途的生物标志物中的 5 个进行的初步验证试验中的相对丰度一致,这些生物标志物的候选生物标志物来自用于发现的患者血清池和构成这些池的单个样本的无标记发现分析。这些结果表明,使用无标记定量策略可以实现稳健、可重复、深入的 3-D 血清蛋白质组发现,以及随后的初步验证研究。